Quoting David Steensma, former Global Head of Hematology at Novartis Institutes for BioMedical Research (NIBR), on X/Twitter:
“I’m excited to have started this new role as Chief Medical Officer of Ajax Therapeutics, focused on developing new medicines for patients with myeloid neoplasms. It is a terrific team and brilliant group of founders led by Ross Levine.”
For details click here.
Source: David Steensma/Twitter